



Published in final edited form as:

Nat Med. ; 17(8): 944–951. doi:10.1038/nm.2392.

## Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11

Masato Sasaki<sup>1,14</sup>, Kohichi Kawahara<sup>2,14</sup>, Miki Nishio<sup>2</sup>, Koshi Mimori<sup>3</sup>, Ryunosuke Kogo<sup>3</sup>, Koichi Hamada<sup>2</sup>, Bunsho Itoh<sup>2</sup>, Jia Wang<sup>2</sup>, Yukako Komatsu<sup>2</sup>, Yong Ryoul Yang<sup>2</sup>, Hiroki Hikasa<sup>2</sup>, Yasuo Horie<sup>4</sup>, Takayuki Yamashita<sup>5</sup>, Takehiko Kamijo<sup>6</sup>, Yanping Zhang<sup>7</sup>, Yan Zhu<sup>8</sup>, Carol Prives<sup>8</sup>, Toru Nakano<sup>9</sup>, Tak Wah Mak<sup>10</sup>, Takehiko Sasaki<sup>1,11</sup>, Tomohiko Maehama<sup>12</sup>, Masaki Mori<sup>3,13</sup>, and Akira Suzuki<sup>1,2</sup>

<sup>1</sup>Global Centers of Excellence Program, Akita University Graduate School of Medicine, Akita, Japan

<sup>2</sup>Division of Cancer Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

<sup>3</sup>Division of Molecular and Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

<sup>4</sup>Department of Gastroenterology, Akita University Graduate School of Medicine, Akita, Japan

<sup>5</sup>Laboratory of Molecular Genetics, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan

<sup>6</sup>Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan

<sup>7</sup>Department of Radiation Oncology and Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA

<sup>8</sup>Department of Biological Sciences, Columbia University, New York, New York, USA

<sup>9</sup>Department of Pathology, Osaka University, Suita, Japan

<sup>10</sup>The Campbell Family Institute for Cancer Research, University Health Network, Toronto, Ontario, Canada

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

Correspondence should be addressed to A.S. (suzuki@bioreg.kyushu-u.ac.jp) or M.M. (mmori@gesurg.med.osaka-u.ac.jp).

<sup>14</sup>These authors contributed equally to this work.

Supplementary information is available on the Nature Medicine website.

### AUTHOR CONTRIBUTIONS

M.S. carried out the initial generation and analyses of *Pict1*<sup>fllox</sup> mice and *Pict1* ES cells. K.K. carried out subsequent major biochemical and biological experiments, and M.N. carried out mouse work. K.M., R.K. and M.M. carried out the human cancer tissue analyses. K.H. generated *Pict1*<sup>-/-</sup> mice. B.I. assisted with confocal microscopy. J.W., Y.K. and Y.R.Y. assisted with the introduction of shRNA into human cancer cell lines. H.H. assisted with the protein binding assays. Y.H. carried out mouse analyses. T.Y., T.K., Y. Zhang, Y. Zhu, C.P. and T.W.M. provided key materials. T.M., K.M. and A.S. conceived of the project, and M.S., K.K., K.M., T.M., M.M. and A.S. designed the experiments. M.S., K.K., M.N., K.M., R.K., T.Y., T.K., Y. Zhang, C.P., T.N., T.W.M., T.S., T.M., M.M. and A.S. discussed the hypothesis and interpreted the data. A.S. coordinated and directed the project and wrote the manuscript.

### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

<sup>11</sup>Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan

<sup>12</sup>Department of Biochemistry and Cell Biology, Japan National Institute of Infectious Diseases, Tokyo, Japan

<sup>13</sup>Department of Gastroenterological Surgery, Medical School and Graduate School of Frontier Biosciences, Osaka University, Suita, Japan

## Abstract

PICT1 (also known as GLTSCR2) is considered a tumor suppressor because it stabilizes phosphatase and tensin homolog (PTEN), but individuals with oligodendrogliomas lacking chromosome 19q13, where *PICT1* is located, have better prognoses than other oligodendroglioma patients. To clarify the function of PICT1, we generated Pict1-deficient mice and embryonic stem (ES) cells. Pict1 is a nucleolar protein essential for embryogenesis and ES cell survival. Even without DNA damage, Pict1 loss led to p53-dependent arrest of cell cycle phase G<sub>1</sub> and apoptosis. Pict1-deficient cells accumulated p53, owing to impaired Mdm2 function. Pict1 binds Rpl11, and Rpl11 is released from nucleoli in the absence of Pict1. In Pict1-deficient cells, increased binding of Rpl11 to Mdm2 blocks Mdm2-mediated ubiquitination of p53. In human cancer, individuals whose tumors express less PICT1 have better prognoses. When PICT1 is depleted in tumor cells with intact P53 signaling, the cells grow more slowly and accumulate P53. Thus, PICT1 is a potent regulator of the MDM2-P53 pathway and promotes tumor progression by retaining RPL11 in the nucleolus

---

Alterations in cell cycle control genes such as the tumor suppressor *TP53* (also known as P53) contribute to tumorigenesis. In response to cellular stress, P53 induces cell cycle arrest or apoptosis. More than 50% of human cancers harbor mutations in *TP53*. In the remainder, the P53 pathway is often inactivated owing to overproduction of MDM2 (mouse double minute 2; ref. 1), an E3 ubiquitin ligase that targets the P53 protein for proteasomal degradation<sup>2,3</sup>. Inhibition of MDM2 therefore leads to P53 protein stabilization and accumulation.

Stresses that activate the MDM2-P53 pathway also induce cascades responsible for its regulation, including the kinases ATM-CHK2 (ataxia telangiectasia mutated–checkpoint kinase 2) and ATR-CHK1 (ataxia telangiectasia and Rad3 related–checkpoint kinase 1). These kinases phosphorylate MDM2 and P53 such that their interaction is abrogated<sup>4</sup>. MDM2 can also be inhibited by P19<sup>ARF</sup> binding triggered by infection or oncogene activation<sup>5,6</sup>; P19<sup>ARF</sup> is one of the transcript products from *CDKN2A* (cyclin-dependent kinase inhibitor 2A) gene. Lastly, stresses that stimulate post-translational modifications such as acetylation or sumoylation of P53 or MDM2 can influence P53 activation<sup>4</sup>.

The MDM2-P53 pathway is also regulated by ribosomal proteins<sup>7</sup>. Upon nucleolar stress, ribosomal proteins RPL5, RPL11, RPL23 and RPS7 translocate from the nucleolus to the nucleoplasm and bind to MDM2 (refs. 8–16). Nucleolar stress is often caused by disruption of ribosomal biogenesis, which in turn can be caused by serum depletion and contact inhibition<sup>17</sup>, agents like low-dose actinomycin D or mycophenolic acid<sup>18,19</sup> or malfunction of nucleolar proteins<sup>13–15,20</sup>. RPL26 increases the translation of *TP53* mRNA in response to

DNA damage<sup>21</sup>, whereas RPS3 protects P53 from MDM2-mediated ubiquitination in response to oxidative stress<sup>22</sup>. Thus, ribosomal proteins can drive P53-mediated responses to stress, but how ribosomal proteins translocate from the nucleolus to the nucleoplasm to exert these functions is unknown. It is also unclear whether genes encoding ribosomal proteins that regulate P53 affect the prognosis of human cancers.

The gene encoding PICT1 (protein interacting with carboxyl terminus-1; also called *GLTSCR2*, glioma tumor suppressor candidate region gene 2) is located at human chromosome 19q13.32, which is frequently altered in human tumors<sup>23</sup>. Low PICT1 expression in diffuse gliomas and ovarian cancers is correlated with high malignant progression<sup>24–26</sup>, whereas PICT1 overexpression enhances apoptosis of cultured glioma cells<sup>27</sup>. At the molecular level, PICT1 stabilizes PTEN via direct physical interaction<sup>28,29</sup>. On the basis of these findings, PICT1 has been deemed a tumor suppressor. Other evidence, however, suggests that PICT1 may not always dampen cancer progression. In oligodendroglial tumors, deletion of the entire chromosome 19q arm, as well as loss of heterozygosity (LOH) at chromosome 19q13 is associated with longer disease-free survival after chemotherapy<sup>30–32</sup>. Nevertheless, in astrocytic gliomas, chromosome 19q deletions are linked to malignant progression<sup>33,34</sup>. These contradictory observations indicate that one or more genes mapped to chromosome 19q may contribute to brain cancer development. We speculated that *PICT1* might be an important chromosome 19q-mapped gene that regulates tumor progression.

To clarify PICT1 functions, we carried out extensive analyses of *Pict1*-deficient mice and ES cells. We show here that PICT1 is a key regulator of ribosomal protein-driven P53-mediated responses to nucleolar stress and that loss of PICT1 inhibits tumor growth owing to stabilization of P53.

## RESULTS

### ***Pict1*-deficient cells show cell cycle arrest and apoptosis**

We generated mice bearing a null mutation of *Pict1* (Supplementary Fig. 1a) but obtained no viable *Pict1*<sup>-/-</sup> pups (Fig. 1a and Supplementary Fig. 1b). Although we observed no morphological differences between *Pict1*<sup>+/+</sup> and *Pict1*<sup>-/-</sup> embryos up to embryonic day 2.75 (E2.75; morula), none of the 15 *Pict1*<sup>-/-</sup> embryos we examined formed proper blastocysts at E3.5 and all contained apoptotic cells (Fig. 1a). This developmental failure was not due to an inadequate uterine environment, because *Pict1*<sup>+/-</sup> embryos of the same litter developed normally. When *Pict1*<sup>-/-</sup> morulae were cultured *in vitro*, they did not mature and died within 2–3 d (Supplementary Fig. 1c). Thus, PICT1 is essential for preimplantation embryogenesis.

To examine PICT1 functions *in vitro*, we generated mutant murine ES cells (*Pict1*<sup>tetTg+</sup>; *Pict1*<sup>-/-</sup>; *Pict1* ES cells) that lacked endogenous *Pict1* owing to gene targeting (Supplementary Fig. 1d,e) but expressed exogenous *Pict1* in a doxycycline-regulatable manner such that *Pict1* expression was ‘on’ without doxycycline (Dox<sup>-</sup>) but ‘off’ after doxycycline treatment (Dox<sup>+</sup>) (Supplementary Methods and Supplementary Fig. 1e,f). Because Dox<sup>-</sup> *Pict1* ES cells behaved like wild-type (WT) ES cells in cell growth, cell cycle and apoptosis assays (Supplementary Fig. 1g,h), we used Dox<sup>-</sup> cells as controls throughout

our study. Doxycycline treatment of *Pict1* ES cells inhibited both *Pict1* expression and cell growth in a dose-dependent manner (Fig. 1b). This growth inhibition was due to both cell cycle arrest (Fig. 1c) and enhanced apoptosis (Fig. 1d). Thus, PICT1 is required for the survival and proliferation of ES cells.

### Effects of *Pict1* loss depend on p53 but not p19<sup>Arf</sup> or Pten

Compared with *Dox*<sup>-</sup> cells, *Dox*<sup>+</sup> cells showed greater expression of p53, p21<sup>Waf1</sup> and p19<sup>Arf</sup> (Fig. 2a) that, at least for p53, was correlated with the degree of doxycycline-mediated *Pict1* suppression (Fig. 2b). The greater p53 expression in *Dox*<sup>+</sup> cells was probably not due to DNA damage, because phospho- $\gamma$ -histone family member X (p $\gamma$ H2ax), which is a marker of DNA damage, was much lower in *Dox*<sup>+</sup> cells than in ultraviolet (UV)-treated cells with comparable p53 activation (Fig. 2c). Moreover, the elevation in p $\gamma$ H2ax owing to UV exposure was not further enhanced by doxycycline (Fig. 2c). Notably, siRNA-mediated p53 knockdown prevented the cell cycle arrest (Fig. 2d and Supplementary Fig. 2a) and increased apoptosis (Fig. 2e) observed in *Dox*<sup>+</sup> cells. Although p19<sup>Arf</sup> expression was greater in *Dox*<sup>+</sup> than in *Dox*<sup>-</sup> cells (Fig. 2a), siRNA-mediated p19<sup>Arf</sup> knockdown did not affect p53 protein expression, cell cycle arrest or apoptosis in *Dox*<sup>+</sup> cells (Supplementary Fig. 2b–d).

The thymus is highly sensitive to p19<sup>Arf</sup>-p53 signaling<sup>35</sup>, and our *Pict1*<sup>-/-</sup> mice succumbed to early embryonic lethality. We therefore generated mice deficient in *Pict1* specifically in T cells by crossing *LckCre* transgenic mice with *Pict1*<sup>fllox</sup> mice (Supplementary Methods). Total number of thymocytes in these mutants were <5% of those in control *Pict1*<sup>fllox/fllox</sup> mice (Fig. 2f), a defect that was markedly rescued in *LckCrePict1*<sup>fllox/fllox</sup>; *Trp53*<sup>-/-</sup> double knockout (DKO) mice (Fig. 2f), but not in *LckCrePict1*<sup>fllox/fllox</sup>; *p19*<sup>Arf</sup><sup>-/-</sup> double-knockout mice (Supplementary Fig. 2e). Consistent with an earlier report<sup>36</sup>, p53 expression was lower in p19<sup>Arf</sup>-deficient T cells than in wild-type cells (Supplementary Fig. 2f). However, because p53 expression is still high in *LckCrePict1*<sup>fllox/fllox</sup>; *p19*<sup>Arf</sup><sup>-/-</sup> double-knockout T cells (Supplementary Fig. 2f) compared with *LckCrePict1*<sup>fllox/fllox</sup>; *p19*<sup>Arf</sup><sup>+/+</sup> T cells, we do not think p19<sup>Arf</sup> mediates the higher expression of p53 associated with loss of *Pict1*.

Despite our observations in T cells deficient in *Pict1*, double-knockout mice that totally lacked *Trp53* and *Pict1* were still embryonic lethal (Supplementary Fig. 3a), suggesting that the phenotype of *Pict1*-deficient embryos involves factors in addition to p53 accumulation. To determine whether PTEN was one of these factors, we examined the stability of Pten protein without *Pict1*. After *Pict1* ES cells with or without doxycycline induction were treated with 100  $\mu$ g ml<sup>-1</sup> cycloheximide, immunoblotting showed that Pten degradation was faster without *Pict1* (Supplementary Fig. 3b). However, expression of steady-state Pten (without cycloheximide), phospho-Pten, and phospho-Akt was comparable in *Dox*<sup>+</sup> and *Dox*<sup>-</sup> cells (Fig. 2a and Supplementary Fig. 3c). Thus, at least in unstimulated cells, PICT1 has only a subtle stabilization effect on PTEN that occurs without obvious phosphorylation of PTEN or effector activation.

### Pict1 deficiency inhibits Mdm2 function

To investigate how Pict1 deficiency increases p53 expression, we first measured *Trp53* mRNA levels by northern blotting. Steady-state levels of *Trp53* mRNA remained constant in Dox<sup>+</sup> cells treated with increasing doxycycline for 2 d (Fig. 3a). Through cycloheximide studies, we found that p53 protein half-life was longer in Dox<sup>+</sup> cells compared to Dox<sup>-</sup> cells (Fig. 3b), but Pict1 deficiency had no effect on p21 protein half-life (data not shown). Studies using the proteasomal inhibitor MG132 showed that the increase in p53 protein half-life was due to protection from proteasomal degradation (Fig. 3c), suggesting that the elevated p53 abundance in Pict1-deficient cells is not due to transcriptional effects.

We hypothesized that PICT1 deficiency prevents P53 degradation by decreasing its MDM2-mediated ubiquitination. We transfected H1299 cells with plasmids expressing hemagglutinin-tagged ubiquitin (HA-Ub), Myc-tagged P53 and T7-tagged MDM2, and we carried out immunoprecipitation and immunoblotting to detect ubiquitinated P53 (Ub-P53). Before immunoprecipitation, we inhibited the 26S proteasome with MG132 to allow accumulation of ubiquitinated proteins. As we expected, coexpression of MDM2 and P53 produced a ladder of Ub-P53 products (Fig. 3d). However, when we also infected these MDM2- and P53-expressing H1299 cells with a lentivirus expressing *PICT1* shRNA, the laddering was less intense (Fig. 3d). Notably, Pict1 deficiency also decreased the Mdm2-dependent ubiquitination of endogenous p53 (Fig. 3e and Supplementary Fig. 2a). These results show that PICT1 inhibition prevents MDM2-mediated P53 ubiquitination.

The accumulation of p53 in doxycycline-treated Pict1 deficient ES cells was dependent on Mdm2 but minimally influenced by depletion of Huwe1, Rfwd2 or Rchy1 (Fig. 3f), other E3 ligases that target p53 in cancer cell lines. Thus, Mdm2 is the major E3 ligase for p53, and other E3 ligases do not contribute to p53 degradation in mouse ES cells, consistent with earlier reports<sup>37,38</sup>. Notably, Mdm2 protein amounts were essentially equal in Dox<sup>-</sup> and Dox<sup>+</sup> cells (Fig. 3g), in contrast to the earlier finding that *Mdm2* is a direct transcriptional target of p53 (ref. 39). The reason for this discrepancy is unclear, but, considering that *Mdm2* mRNA levels are elevated in the absence of Pict1 (Fig. 3a), a previously uncharacterized post-transcriptional mechanism may suppress Mdm2 protein without Pict1. The low p53 ubiquitination in Dox<sup>+</sup> cells is not simply due to low p53-Mdm2 binding (Supplementary Fig. 4), and is probably caused by inactivation of the E3 ligase function of Mdm2 induced by loss of Pict1.

### PICT1 regulates MDM2 by retaining RPL11 in the nucleolus

MDM2 function is influenced by nucleolar ribosomal proteins<sup>7,13</sup> and other nucleolar proteins such as nucleophosmin<sup>40</sup>. When we expressed Pict1-EGFP and nucleophosmin-DsRed fusion proteins in 293T cells, these exogenous proteins colocalized in nucleoli (Supplementary Fig. 5a). Pict1 was also highly expressed in the nucleolus of Dox<sup>-</sup> cells (Fig. 4a). Nucleostemin and nucleolin are also key nucleolar proteins that regulate P53. Although deficiency in nucleophosmin, nucleostemin or nucleolin causes P53 accumulation<sup>40-42</sup>, the endogenous expression and localization of none of these proteins was impaired in Dox<sup>+</sup> cells (Fig. 4a and Supplementary Fig. 5b,c).

To identify intracellular binding partners of PICT1, we expressed *Flag-PICT1* cDNA in 293T cells, immunoprecipitated the protein with antibody to Flag, and carried out nanoscale liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS; Supplementary Methods). Pict1 bound a huge complex containing many ribosomal proteins (Supplementary Fig. 5d). Among these ribosomal proteins, RPL5 and RPL11 inhibit MDM2-mediated P53 ubiquitination<sup>8-10</sup>. When we examined the binding of purified ribosomal protein fusion proteins to Pict1 *in vitro*, RPL5 and RPL11, which we identified in our LC-MS/MS experiments, and RPS7 and RPL23, which inhibit MDM2-mediated P53 ubiquitination<sup>11,12</sup>, physically interacted with Pict1 (Supplementary Fig. 5e). We confirmed this binding *in vivo* by expressing exogenous Myc-ribosomal proteins and Flag-Pict1 in 293T cells and subjecting them to immunoprecipitation (Supplementary Fig. 5f).

To determine whether any of these ribosomal proteins was responsible for the impaired Mdm2 function observed in Dox<sup>+</sup> cells, we carried out siRNA-mediated knockdown experiments and found that only siRNA against *Rpl11* blocked p53 accumulation in Dox<sup>+</sup> cells (Fig. 4b). Furthermore, the degree of Rpl11 suppression achieved with various *Rpl11* siRNAs was correlated with the degree of suppression of p53 accumulation in Dox<sup>+</sup> cells (Supplementary Fig. 5g). We also confirmed the binding of endogenous Rpl11 to Pict1 in untreated Dox<sup>-</sup> cells by immunoprecipitation (Fig. 4c).

We next compared RPL11 localization in Dox<sup>-</sup> and Dox<sup>+</sup> cells. Exogenous RPL11 appeared in both the nucleolus and cytoplasm in Dox<sup>-</sup> cells but was almost completely translocated out of the nucleolus in Dox<sup>+</sup> cells (Fig. 4d,e). However, exogenous RPL5, RPL23 and RPS7 did not translocate out of the nucleolus in Dox<sup>+</sup> cells (Supplementary Fig. 6a-c). We observed the same patterns for endogenous Rpl11, Rpl5, Rpl23 and Rps7 proteins (Fig. 4a). Immunostaining for nucleophosmin, nucleolin and nucleostemin confirmed that nucleoli were intact in our Dox<sup>+</sup> cells (Fig. 4d and Supplementary Figs. 5c and 6a-d). Thus, PICT1 is essential for the nucleolar localization of RPL11.

Because RPL11 inhibits MDM2-mediated P53 ubiquitination by binding MDM2 (refs. 7-9,13), we analyzed RPL11-Mdm2 colocalization and binding using our Dox<sup>+</sup> cells. Immunostaining confirmed that endogenous Mdm2 was present in the nucleoplasm in both Dox<sup>-</sup> and Dox<sup>+</sup> cells (Supplementary Fig. 6d) and that RPL11 and Mdm2 proteins colocalized in the nucleoplasm of Dox<sup>+</sup> cells (Fig. 4f). In addition, binding of endogenous Mdm2 to Rpl11 was much greater in the nucleus of Dox<sup>+</sup> cells than in that of Dox<sup>-</sup> cells (Fig. 4g and Supplementary Fig. 6e). We hypothesize that, when PICT1 is not present to retain RPL11 in the nucleolus, RPL11 escapes into the nucleoplasm and binds MDM2, blocking its ubiquitination of P53. As a result, p53 accumulates in Dox<sup>+</sup> cells. PICT1 is therefore a crucial nucleolar binding partner of RPL11 that regulates the MDM2-P53 pathway.

### Suppression of PICT1 inhibits tumor cell growth

Although earlier data suggest that PICT1 is a tumor suppressor, we found that Pict1 loss led to p53 accumulation and presumed protection from oncogenesis. We therefore analyzed the onset of chemically induced skin cancers in *Pict1*<sup>+/-</sup> mice. Compared with *Pict1*<sup>+/+</sup> controls, *Pict1*<sup>+/-</sup> mice were more resistant to papillomagenesis (Fig. 5a). Similarly, shRNA-mediated



Author Manuscript

suppression of PICT1 in various *TP53*-intact cell lines derived from human gliomas or colorectal or ovarian tumors led to growth inhibition and P53 accumulation without alterations in PTEN or phospho-AKT expression (Fig. 5b). We observed neither growth inhibition nor P53 accumulation in *TP53*-mutated or P53-inactivated tumor cell lines that were treated with *PICT1* shRNA (Supplementary Fig. 7a). Thus, PICT1 does not seem to function as a tumor suppressor when P53 signaling is intact.

Author Manuscript

We next determined whether *PICT1* expression is correlated with human colorectal or esophageal cancer progression. We detected *TP53* mutations in ~40% of our colorectal and esophageal cancer specimens, consistent with earlier reports<sup>43,44</sup>. Of 181 colorectal cancers examined, individuals whose tumors had a ratio of *PICT1* mRNA to *GAPDH* mRNA of <0.58 were classified in the PICT1<sup>low</sup> group ( $n = 90$ ), whereas those with ratios  $\geq 0.58$  were classified in the PICT1<sup>high</sup> group ( $n = 91$ ) (Supplementary Fig. 7b). The 5-year overall survival rates for the PICT1<sup>high</sup> and PICT1<sup>low</sup> groups were 62.0% and 81.0%, respectively, but only when *TP53*-intact cases were considered (Fig. 5c). We found the same pattern in 81 individuals with esophageal cancer: individuals whose tumors had a ratio of *PICT1* mRNA to *GAPDH* mRNA of <0.64 were classified as PICT1<sup>low</sup> ( $n = 40$ ), and those with ratios  $\geq 0.64$  were classified as PICT1<sup>high</sup> ( $n = 41$ ) (Fig. 5c and Supplementary Fig. 7b). The 5-year overall survival rates for these PICT1<sup>high</sup> and PICT1<sup>low</sup> groups (*TP53*-intact cases only) were 24.5% and 42.1%, respectively. We observed no difference in 5-year survival in *TP53*-mutated cases of either colorectal or esophageal cancer (Fig. 5c). The Cox proportional hazards model showed that *PICT1* mRNA level was an independent prognostic predictor for individuals with either colorectal or esophageal cancer (Supplementary Fig. 7c). Thus, low PICT1 expression is associated with low tumor cell growth *in vitro* and *in vivo* and with a better prognosis in individuals with cancer.

## DISCUSSION

Author Manuscript

Author Manuscript

Although *PICT1* has been designated a tumor suppressor gene<sup>24–28,45</sup>, our work implicates PICT1 as a potentially oncogenic regulator of the MDM2-P53 pathway. Inhibition of Pict1 in ES cells and in various *TP53*-intact cancer cell lines led to P53 accumulation that inhibited cell growth *in vitro*. *In vivo*, *Pict1*<sup>+/-</sup> mice were resistant to chemically induced skin tumors; T cell-specific Pict1-deficient mice showed p53-dependent T cell developmental arrest; and individuals with colorectal or esophageal tumors with low *PICT1* expression and without *TP53* mutation had a better prognosis. Thus, *PICT1* is a key cancer-related gene that primarily regulates P53 but is not a typical tumor suppressor. Consistent with our finding that *PICT1* knockdown inhibited the growth of *TP53*-intact glioma cells (Fig. 5b), oligodendroglial tumors with loss of chromosome 19q13 have a better disease outcome<sup>30–32</sup>. Indeed, oligodendroglomas show frequent loss of chromosome 19q (70%) but infrequent *TP53* mutations (<15%)<sup>46</sup>. In our study, loss of PICT1 only slightly affected PTEN stability and led to a P53 accumulation in *TP53*-intact cells that inhibited proliferation. However, PICT1 inhibition has been linked to AKT activation in some insulin-treated cell lines<sup>29</sup>. Thus, PICT1 may act as a tumor suppressor under limited conditions that include loss of P53 function.

Although P53 is activated by ribosomal proteins released from the nucleolus after nucleolar stress<sup>8-12</sup>, it was unclear how these ribosomal proteins are anchored in the nucleolus. We have shown that Pict1 binds to and retains RPL11 in the nucleolus, preventing RPL11 from inhibiting Mdm2 in the nucleoplasm. Consistent with this model (Fig. 6), treatment of WT ES cells with a low dose of actinomycin D or mycophenolic acid decreased Pict1 expression and p53 accumulation (Supplementary Fig. 8). Small ribosomal subunit proteins in the nucleolus are unstable and degraded in response to stress signals<sup>47</sup>. However, we found that amounts of ribosomal proteins other than Rpl11, including Rps7, were not decreased in the nucleolus by Pict1 deficiency. In addition, the decrease in endogenous p53 ubiquitination without Pict1 was notable after the addition of MG132, and Rpl11 suppression blocked p53 accumulation in Pict1 ES cells. Thus, we think that protein degradation did not cause the observed decrease in nucleolar Rpl11, and that without retention by PICT1, RPL11 diffuses into the nucleoplasm, where it is captured by MDM2. We showed that Pict1 loss enhanced Rpl11-Mdm2 binding in the nucleoplasm and inhibited the E3 ligase activity of Mdm2, leading to p53-dependent cell cycle arrest and apoptosis in a manner consistent with earlier results<sup>8</sup>. PICT1 is therefore a major upstream regulator of P53, and the binding of PICT1 to RPL11 controls the MDM2-P53 pathway.

In conclusion, our work shows that PICT1 is a key regulator that acts primarily through RPL11 and MDM2 to inhibit P53 responses to nucleolar stress. We have also identified PICT1 as a useful prognostic marker for human colorectal and esophageal cancers. Studies of factors influencing PICT1 expression or stability, or interfering with PICT1-RPL11 binding, may yield new cancer treatments, especially for individuals with *TP53*-intact tumors.

## ONLINE METHODS

### Pict1-deficient ES cells

We electroporated *Pict1*<sup>fllox</sup> targeting vector (Supplementary Fig. 1d and Supplementary Methods) into *Pict1*<sup>+/-</sup> ES cells (Supplementary Fig. 1a), and used correctly targeted clones (*Pict1*<sup>3loxP/-</sup>; Supplementary Fig. 1e) to generate Tet-regulated ES cells. We established an ES cell clone that constitutively expressed the modified Tet-regulated transactivator driven by the CAG promoter<sup>48</sup> and co-transfected these cells with Tet-regulatable pUHD10-3Pict1.IRES.EGFP plasmid<sup>48</sup> plus pcDNA3.1Zeo. We selected transfected cells for 10 d in medium containing 20  $\mu\text{g ml}^{-1}$  zeocin (Invitrogen) and studied clones whose EGFP expression was tightly regulated by tetracycline (Supplementary Fig. 1f). We examined expression of the modified *Pict1* genes by immunoblotting to confirm that exogenous *Pict1* was driven by the Tet response promoter (*tetO-CMV*) and suppressed by Tet addition (Tet-off system)<sup>49</sup>. We transiently transfected Tet-regulatable Pict1-deficient ES cells (*Pict1tetTg*<sup>+</sup>; *Pict1*<sup>3loxP/-</sup>; Supplementary Fig. 1e) with *CAGGS-Cre* DNA to eliminate the endogenous *Pict1* allele. The desired mutant Pict1 ES cell clone (*Pict1tetTg*<sup>+</sup>; *Pict1*<sup>-/-</sup>) was maintained without Dox after *Cre* DNA transfection (Dox<sup>-</sup> cells). We added Dox (5 ng ml<sup>-1</sup>) to Pict1 ES cells to delete Pict1 and generate Dox<sup>+</sup> cells (Supplementary Fig. 1e).



## Immunoblotting

We carried out immunoblotting using a standard protocol and primary antibodies to PTEN (Cascade), phospho-PTEN, phospho-Akt, Akt, phospho- $\gamma$ -H2ax (all from Cell Signaling), mouse p53 (Novocastra), human P53 (Santa Cruz), p21<sup>Waf1</sup> (Calbiochem), p19<sup>Arf</sup> (Abcam), p16<sup>Ink4a</sup> (Santa Cruz), p27<sup>Kip1</sup> (BD Biosciences), human ubiquitin (Santa Cruz), RPL5 (Abcam), nucleostemin (Millipore), nucleophosmin, nucleolin and actin (all from Sigma). Antibodies to PICT1, RPL11, RPL23 and RPS7 were affinity-purified from antisera as previously described<sup>9,11,12,50</sup>. We detected primary antibodies using horseradish peroxidase-conjugated secondary antibodies (Cell Signaling).

## Transfection of siRNA and shRNA

We transfected siRNA oligonucleotides (10 nM) in OPTI-MEM (Invitrogen) into cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. At 24 h after transfection, Pict1 was deleted by Dox treatment at concentrations and for the times indicated in Figures 2d,e, 3e,f and 4b and Supplementary Figures 2a–d and 5g. We assayed protein levels as described below. Target sequences for siRNAs are in Supplementary Methods.

For shRNA studies, we produced lentiviruses containing *PICT1* shRNA or scrambled shRNA (lenti-shRNA) and used them to infect tumor cells as previously described<sup>51</sup>. We estimated lentivirus titers by measuring HIVp24 gag antigen concentration using ELISA (PerkinElmer Life Science). For Figure 5b and Supplementary Figure 7a, we incubated tumor cells in six-well plates ( $5 \times 10^4$  per well) with lenti-shRNA ( $1.5 \times 10^4$  transduction units) for 6 d. Gene transfection efficiency was 80–97%. Proliferation of infected cells was determined by MTS assay (Promega). Target sequences for shRNAs are in Supplementary Methods.

## Ubiquitin ligase activity

We assayed ubiquitin ligase activity as described<sup>52,53</sup> with minor modifications outlined in Supplementary Methods.

## Immunoprecipitation

To detect the binding of exogenous ribosomal proteins to Pict1, we transfected the appropriate pcDNA3.1-Myc-RP cDNA plus CAG-Flag-Pict1 cDNA into 293T cells (RIKEN BioResource Center) by lipofection. At 48 h after transfection, cells were lysed and analyzed by immunoprecipitation (Supplementary Fig. 5f). To detect the binding of endogenous Pict1 to Rpl11 (Fig. 4c), Mdm2 to Rpl11 (Fig. 4g and Supplementary Fig. 6e) and Mdm2 to p53 (Supplementary Fig. 4), we lysed Pict1 ES cells at various times after addition of  $5 \text{ ng ml}^{-1}$  doxycycline and incubated them with antibodies to Pict1, Mdm2 (Santa Cruz), Rpl11 or p53 (Novocastra) or control IgG (Santa Cruz). We adsorbed immune complexes to protein G-Sepharose beads (GE). When used, we added MG132 (20  $\mu\text{M}$ ) 3 h before cell collection. After washing extensively, we analyzed samples by immunoblotting with antibodies to Rpl11, Pict1, Mdm2 or p53.

## Chemical tumor induction

To induce tumors, we topically treated shaved dorsal skin of *Pict1*<sup>+/+</sup> ( $n = 17$ ) and *Pict1*<sup>+/-</sup> ( $n = 19$ ) mice (6–7 weeks old) with 0.5 mg 7,12-dimethylbenz[*a*]anthracene (Sigma) in acetone. Two weeks later, the same area was topically treated with 5  $\mu$ g phorbol-12-myristate-13-acetate (Sigma) in acetone twice weekly for 22 weeks as described<sup>51</sup>. Control mice were treated with acetone only. We measured tumor numbers and sizes weekly. The Institutional Review Board of Kyushu University approved the design of all animal studies.

## Clinical samples

We acquired surgically obtained colorectal (181) and esophageal (81) cancer samples from the Department of Surgical Oncology, Kyushu University. The Institutional Research Ethics Committee of Kyushu University approved the study design, and all study participants gave written informed consent. We immediately froze resected cancer tissues in liquid nitrogen. We determined mutation of *TP53* by sequencing a DNA region spanning exons 5–8, the area where most *TP53* mutations occur<sup>43</sup>. We analyzed *PICT1* and control *GAPDH* mRNA levels using quantitative real-time RT-PCR and JMP 5 for Windows software (SAS Institute). We established survival curves using Kaplan-Meier methodology and examined differences using the log-rank test. We calculated relative risk using the Cox proportional hazard model.  $P < 0.05$  indicates statistical significance.

## Additional methods

Detailed methodology is described in the Supplementary Methods.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We are grateful to T. Noda, S. Kuroda, H. Kishimoto, M. Natsui, H. Takahashi, H. Tashiro, N. Yasui, M. Suzuki, S. Suzuki, T. Shono and T. Sasaki for expert technical support and helpful discussions. We also thank H. Miyoshi (RIKEN BioResource Center, Tsukuba, Japan) for providing lentivirus vector plasmid DNA. This work was supported by grants from the Ministry of Education, Culture, Sports and Technology of Japan (MEXT), Takeda Medical Foundation, Naito Foundation, Ono Medical Research Foundation, Yasuda Medical Foundation, and Astellas Foundation for Research on Metabolic Disorders. K.M. and M.M. are supported by the Core Research for Evolutionary Science and Technology program of the Japanese Science and Technology Agency. T.Y., T.S., M.M. and A.S. are supported by the Global Centers of Excellence Program of MEXT.


## References

1. Toledo F, Wahl GM. Regulating the p53 pathway: *in vitro* hypotheses, *in vivo* veritas. *Nat. Rev. Cancer*. 2006; 6:909–923. [PubMed: 17128209]
2. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature*. 1997; 387:299–303. [PubMed: 9153396]
3. Haupt Y, Maya R, Kazanietz A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature*. 1997; 387:296–299. [PubMed: 9153395]
4. Kruse JP, Gu W. Modes of p53 regulation. *Cell*. 2009; 137:609–622. [PubMed: 19450511]
5. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell*. 1998; 92:725–734. [PubMed: 9529249]

6. Pomerantz J, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell*. 1998; 92:713–723. [PubMed: 9529248]
7. Lindström MS, Deisenroth C, Zhang Y. Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions. *Cell Cycle*. 2007; 6:434–437. [PubMed: 17329973]
8. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. *Cancer Cell*. 2003; 3:577–587. [PubMed: 12842086]
9. Zhang Y, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. *Mol. Cell. Biol.* 2003; 23:8902–8912. [PubMed: 14612427]
10. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. *J. Biol. Chem.* 2004; 279:44475–44482. [PubMed: 15308643]
11. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. *Mol. Cell. Biol.* 2004; 24:7669–7680. [PubMed: 15314174]
12. Zhu Y, et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. *Mol. Cell.* 2009; 35:316–326. [PubMed: 19683495]
13. Fumagalli S, et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rPL11-translation-dependent mechanism of p53 induction. *Nat. Cell Biol.* 2009; 11:501–508. [PubMed: 19287375]
14. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. *Cancer Cell*. 2009; 16:369–377. [PubMed: 19878869]
15. Warner JR, McIntosh KB. How common are extraribosomal functions of ribosomal proteins? *Mol. Cell.* 2009; 34:3–11. [PubMed: 19362532]
16. Chen D, et al. Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. *Oncogene*. 2007; 26:5029–5037. [PubMed: 17310983]
17. Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. *EMBO J.* 2004; 23:2402–2412. [PubMed: 15152193]
18. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. *EMBO J.* 2003; 22:6068–6077. [PubMed: 14609953]
19. Sun XX, Dai MS, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. *J. Biol. Chem.* 2008; 283:12387–12392. [PubMed: 18305114]
20. Sulic S, et al. Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. *Genes Dev.* 2005; 19:3070–3082. [PubMed: 16357222]
21. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. *Cell*. 2005; 123:49–63. [PubMed: 16213212]
22. Yadavilli S, et al. Ribosomal protein S3: a multi-functional protein that interacts with both p53 and MDM2 through its KH domain. *DNA Repair (Amst.)*. 2009; 8:1215–1224. [PubMed: 19656744]
23. Smith JS, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. *Genomics*. 2000; 64:44–50. [PubMed: 10708517]
24. Kim YJ, et al. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas. *J. Pathol.* 2008; 216:218–224. [PubMed: 18729076]
25. Nakagawa Y, et al. Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization. *Oncol. Rep.* 2006; 15:297–303. [PubMed: 16391845]
26. Merritt MA, et al. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. *BMC Cancer*. 2009; 9:378. [PubMed: 19849863]
27. Yim JH, et al. The putative tumor suppressor gene GLTSCR2 induces PTEN-modulated cell death. *Cell Death Differ.* 2007; 14:1872–1879. [PubMed: 17657248]
28. Okahara F, Ikawa H, Kanaho Y, Maehama T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. *J. Biol. Chem.* 2004; 279:45300–45303. [PubMed: 15355975]

29. Okahara F, et al. Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. *Mol. Biol. Cell.* 2006; 17:4888–4895. [PubMed: 16971513]
30. Cairncross JG, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. *J. Natl. Cancer Inst.* 1998; 90:1473–1479. [PubMed: 9776413]
31. Smith JS, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. *Oncogene.* 1999; 18:4144–4152. [PubMed: 10435596]
32. Mariani L, et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. *J. Clin. Oncol.* 2006; 24:4758–4763. [PubMed: 16966689]
33. von Deimling A, et al. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. *Cancer Res.* 1994; 54:1397–1401. [PubMed: 8137236]
34. Smith JS, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. *J. Clin. Oncol.* 2000; 18:636–645. [PubMed: 10653879]
35. Miyazaki M, et al. Thymocyte proliferation induced by pre-T cell receptor signaling is maintained through polycomb gene product Bmi-1-mediated Cdkn2a repression. *Immunity.* 2008; 28:231–245. [PubMed: 18275833]
36. Kamijo T, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc. Natl. Acad. Sci. USA.* 1998; 95:8292–8297. [PubMed: 9653180]
37. Solozobova V, Blattner C. Regulation of p53 in embryonic stem cells. *Exp. Cell Res.* 2010; 316:2434–2446. [PubMed: 20542030]
38. Zhao X, et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. *Nat. Cell Biol.* 2008; 10:643–653. [PubMed: 18488021]
39. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. *EMBO J.* 1993; 12:461–468. [PubMed: 8440237]
40. Kurki S, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. *Cancer Cell.* 2004; 5:465–475. [PubMed: 15144954]
41. Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. *Mol. Cell. Biol.* 2008; 28:4365–4376. [PubMed: 18426907]
42. Saxena A, Rorie CJ, Dimitrova D, Daniely Y, Borowiec JA. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. *Oncogene.* 2006; 25:7274–7288. [PubMed: 16751805]
43. Russo A, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. *J. Clin. Oncol.* 2005; 23:7518–7528. [PubMed: 16172461]
44. Egashira A, et al. p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries. *Cancer Sci.* 2007; 98:1152–1156. [PubMed: 17573896]
45. Kim JY, Kim HS, Lee S, Park JH. The expression of GLTSCR2, a candidate tumor suppressor, is reduced in seborrheic keratosis compared to normal skin. *Pathol. Res. Pract.* 2010; 206:295–299. [PubMed: 20185249]
46. Okamoto Y, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. *Acta Neuropathol.* 2004; 108:49–56. [PubMed: 15118874]
47. Andersen JS, et al. Nucleolar proteome dynamics. *Nature.* 2005; 433:77–83. [PubMed: 15635413]
48. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. *Proc. Natl. Acad. Sci. USA.* 2000; 97:1737–1742. [PubMed: 10677527]
49. Kitajima K, Masuhara M, Era T, Enver T, Nakano T. GATA-2 and GATA-2/ER display opposing activities in the development and differentiation of blood progenitors. *EMBO J.* 2002; 21:3060–3069. [PubMed: 12065419]


50. Okahara F, et al. Production of research-grade antibody by *in vivo* electroporation of DNA-encoding target protein. *Anal. Biochem.* 2005; 336:138–140. [PubMed: 15582570]
51. Inoue-Narita T, et al. Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. *Cancer Res.* 2008; 68:5760–5768. [PubMed: 18632629]
52. Furukawa M, Zhang Y, McCarville J, Ohta T, Xiong Y. The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1. *Mol. Cell. Biol.* 2000; 20:8185–8197. [PubMed: 11027288]
53. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. *Mol. Cell. Biol.* 2005; 25:5389–5395. [PubMed: 15964796]

**Figure 1.**


*Pict1* loss impairs survival of mouse embryos and ES cells. **(a)** Top, morphologies of representative *Pict1*<sup>+/+</sup>, *Pict1*<sup>+/-</sup> and *Pict1*<sup>-/-</sup> embryos at the E3.5 blastocyst stage and the E2.75 morula stage (after compaction). Bottom, TUNEL staining of *Pict1*<sup>+/+</sup>, *Pict1*<sup>+/-</sup> and *Pict1*<sup>-/-</sup> embryos at E3.5. +/+DNase, DNase-treated E3.5 *Pict1*<sup>+/+</sup> embryos (positive control). DAPI, nuclear staining. Scale bar, 50  $\mu$ m. **(b)** Top, semiquantitative RT-PCR of *Pict1* mRNA in *Pict1* ES cells treated for 24 h with doxycycline (Dox) as indicated. *Actb*, loading control. Bottom, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay of proliferation of *Pict1* ES cells treated with Dox as indicated. Results are mean cell growth ( $A_{490}$ ) of three cultures per dose per time point. **(c)** Left, representative FACS profiles of *Pict1* ES cells treated with or without Dox (5 ng ml<sup>-1</sup>) for 1, 2 or 3 d, stained with propidium iodide (PI), and analyzed by flow cytometry. Numbers indicate percentage of cells in G<sub>0</sub>/G<sub>1</sub>, S or G<sub>2</sub>/M phase. Right, mean  $\pm$  s.e.m. percentage of ES cells in G<sub>0</sub>/G<sub>1</sub> phase ( $n = 5$ ). \* $P < 0.01$ . **(d)** Left, representative FACS profile of *Pict1* ES cells treated with or without Dox (5 ng ml<sup>-1</sup>) for 2, 3 or 4 d, stained with TUNEL and analyzed by FACS. Right, mean  $\pm$  s.e.m. percentage of TUNEL<sup>+</sup> ES cells ( $n = 5$ ). \* $P < 0.01$ . Results represent four trials.





**Figure 3.**

Pict1 deficiency inhibits Mdm2 function. **(a)** Northern blot detecting indicated mRNAs in Pict1 ES cells treated for 48 h with Dox. **(b)** Immunoblot detecting p53 and Pict1 in Pict1 ES cells treated for 48 h with or without 5 ng ml<sup>-1</sup> Dox and with or without cycloheximide (CHX; 100 μg ml<sup>-1</sup>). **(c)** Immunoblot detecting p53 in Pict1 ES cells treated for 36 h with or without 5 ng ml<sup>-1</sup> Dox, with or without MG132 (20 μM). **(d)** Immunoblot of H1299 cells transfected with the indicated plasmids and treated with MG132 (20 μM). Lysates were immunoprecipitated and immunoblotted with antibodies to HA (ubiquitin, Ub) and Myc (ubiquitinated p53). **(e)** Immunoblot of Pict1 ES cells transfected with scramble siRNA or *Mdm2* siRNA (*siMdm2*) and treated with or without 5 ng ml<sup>-1</sup> Dox for 48 h. MG132 (20 μM) was added for 3 h before lysis. The p53 protein level in each sample was adjusted to equality before immunoprecipitation with antibody to p53 or to ubiquitin. **(f)** Pict1 ES cells were transfected with scramble siRNA or the indicated siRNAs and treated with or without 5 ng ml<sup>-1</sup> Dox for 24 h. Top, immunoblot detecting indicated proteins. Bottom, quantification of ratio of p53 to actin using LAS Image Analyzer with Multi Gauge Software. **(g)** Immunoblot detecting indicated proteins in Pict1 ES cells treated with or without 5 ng ml<sup>-1</sup> Dox for 48 h. Results represent three trials.

**Figure 4.**

Pict1 regulates Mdm2 by binding to nucleolar Rpl11. **(a)** Immunoblot detecting indicated proteins in cytoplasmic, nuclear and nucleolar fractions (30  $\mu$ g) of Pict1 ES cells treated for 1 or 2 d with or without 5 ng ml<sup>-1</sup> Dox. Nucleostemin (Nsm), lamin and tubulin, localization controls. **(b)** Immunoblot detecting the indicated proteins in Pict1 ES cells transfected with vehicle (No), scramble siRNA, *Trp53* siRNA (positive control) or siRNAs against the indicated ribosomal proteins and treated with or without 5 ng ml<sup>-1</sup> Dox for 24 h. **(c)** Immunoblot of untreated Dox<sup>-</sup> ES cells immunoprecipitated and immunoblotted with antibodies to Pict1 and Rpl11, respectively. **(d,e)** Confocal microscopy of Pict1 ES cells transfected with plasmid encoding *RPL11-DsRed* and treated with or without 5 ng ml<sup>-1</sup> Dox for 24 h or 48 h. Endogenous nucleophosmin (Npm) was detected using antibody to Npm (green). Cell fluorescence at 24 h is in **d**, and percentages of cells retaining RPL11 in the nucleolus at 24 h and 48 h is graphed in **(e)**. Scale bars, 5  $\mu$ m. **(f)** Confocal microscopy of Pict1 ES cells transfected with plasmid encoding *RPL11-DsRed* and treated with or without 5 ng ml<sup>-1</sup> Dox for 48 h. Endogenous Mdm2 was detected with antibody to Mdm2 (green). Scale bars, 5  $\mu$ m. **(g)** Immunoblot of cytoplasmic and nuclear fractions of Pict1 ES cells treated with or without 5 ng ml<sup>-1</sup> Dox for 2 d. Rpl11 was quantified by immunoblotting and the Rpl11 protein level in each sample was adjusted to equality before immunoprecipitation


with antibody to Rpl11. Lysates were immunoprecipitated with control IgG or antibody to Rpl11 followed by immunoblotting to detect Mdm2. Results represent three trials.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript



**Figure 5.** Reduced cancer growth and better survival with low PICT1. **(a)** *Pict1*<sup>+/+</sup> and *Pict1*<sup>+/-</sup> mice treated with DMBA plus TPA were monitored for papillomagenesis for 22 weeks. Left, gross tumor appearance. Scale bars, 2 mm. Middle, number of papillomas per mouse at 22 weeks (mean ± s.e.m., \**P* < 0.05). Right, incidence and diameter of papillomas at the indicated number of weeks after TPA. **(b)** Human glioma cell lines DBTRG-05MG and D247, colorectal cancer cell lines Lovo and RKO, and ovarian cancer cell line RMG-1 (all WT *TP53*) were treated with scramble shRNA or shRNA against *PICT1* (*PICT1-1* and *PICT1-2*). Top, MTS assay of growth inhibition. Bottom, immunoblot detecting indicated proteins. Results represent three trials. **(c)** Left, Kaplan-Meier survival curves for 181 individuals with colorectal cancer and 81 individuals with esophageal cancer whose tumors showed low *PICT1* mRNA (blue) or high *PICT1* mRNA (orange). Middle, Kaplan-Meier curves for 67 individuals with colorectal cancer and 45 individuals with esophageal cancer whose tumors showed WT *TP53* and high or low *PICT1* mRNA. Right, Kaplan-Meier curves for 45 individuals with colorectal cancer and 34 individuals with esophageal cancer whose tumors showed mutated *TP53* and high or low *PICT1* mRNA.



**Figure 6.** PICT1 binding to nucleolar RPL11 regulates MDM2-P53 activity. Model of PICT1 function. Left, when PICT1 is present in the nucleolus, RPL11 is retained in the nucleolus and MDM2 is free to ubiquitinate P53, promoting its degradation. Right, when PICT1 is absent, nucleolar RPL11 escapes into the nucleoplasm and binds to MDM2, blocking its ubiquitination of P53. As a result, P53 accumulates in PICT1-deficient cells.